Results 41 to 50 of about 5,866 (194)

An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer

Breast, 2023
Purpose: Pegfilgrastim is a widely used long-acting granulocyte colony-stimulating factor (G-CSF) that prevents febrile neutropenia (FN) in patients with breast cancer receiving chemotherapy.
Anbok Lee, Taewoo Kang, Su Hwan Kang, Woo-Chan Park, Woosung Lim, Myung-Chul Chang, Hyun Yul Kim, Jeong-yoon Song, Jihyoun Lee, Kyung Do Byun, Hyun-Ah Kim, Gil Soo Son, Ju-Yeon Kim, Se Jeong Oh, Min Sung Chung, Young Jin Choi, Hyuk-Jai Shin, Jong Min Baek, Youngbum Yoo, Eunhae Um, Jin Hyuk Choi, Beom Seok Kwak, Min Ho Park, Suok Hyun Lee, Cheol Seung Kim, Ilkyun Lee, Je-Ryong Kim, Han Shin Lee, Cheol Wan Lim   +28 more
doaj   +1 more source

An Unusual Case Presentation on Docetaxel Induced Lung Injury

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Docetaxel can rarely cause acute interstitial lung injury early in therapy. New‐onset cough, fever, or dyspnea after chemotherapy should prompt immediate evaluation, exclusion of infection, and high‐resolution CT imaging. Early drug withdrawal and timely corticosteroid therapy can result in rapid clinical recovery and prevent serious morbidity.
Soorej Balan Kaliyath, S. Pavani, Arup Kumar Misra, A. Kesav Ramgopal, S. Yugandhar, Sushil Sharma, L. V. Simhachalam Kutikuppala, Golla Varshitha   +7 more
wiley   +1 more source

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

BMC Cancer, 2008
Background Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound neutropenia following induction and/or consolidation chemotherapy and this may result in ...
Noga Stephen J, Thomas Xavier, Lazzarino Mario, Herrmann Richard, Kassis Jeannine, Szer Jeffrey, Sierra Jorge, Baker Nigel, Dansey Roger, Bosi Alberto   +9 more
doaj   +1 more source

Is It Better to Mobilize Hematopoietic Stem Cells With Pegfilgrastim in Healthy Donors During Allogeneic Hematopoietic Stem Cell Transplantation?

Frontiers in Oncology, 2020
The mobilization of hematopoietic stem cells (HSCs) using granulocyte colony-stimulating factor is a classic method. Recently, a single injection of pegfilgrastim was used to mobilize CD34+ cells in some small-sample studies.
Jiali Li, Jiali Li, Sanbin Wang, Yicheng Zhang, Shifeng Lou, Yao Liu, Yao Liu, Peiyan Kong, Peiyan Kong, Cheng Zhang, Cheng Zhang, Lei Gao, Lei Gao, Xiangui Peng, Xiangui Peng, Ping Wang, Ping Wang, Xiaojuan Deng, Xiaojuan Deng, Li Gao, Li Gao, Xi Zhang, Xi Zhang   +22 more
doaj   +1 more source

Immunocompromised Status Definition in Observational Studies Using Electronic Health Records: A Scoping Review and a Proposal for a Phenotype Identification Algorithm

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Immunocompromised individuals experience an impaired immune function due to conditions that might be either congenital or acquired over the course of their lives. Epidemiological studies often rely on clinical definitions which, in some cases, benefit from being translated into machine‐readable algorithms for application to electronic health ...
Judit Riera‐Arnau, Nicoletta Luxi, Fabio Riefolo, Martín Solorzano, Irene Pazos, Elena Ballarín, Lise Skovgaard Svingel, Lorenzo Chiusaroli, Elisa Martín‐Merino, Elisa Barbieri, María Lopez‐Lasanta, Sima Mohammadi, Denis Rotta, Alexandra Pacurariu, Catherine Cohet, Miriam Sturkenboom, Carlos E. Durán, on behalf of the SAFETY‐VAC study consortium, Carlos E. Durán, Miriam Sturkenboom, Judit Riera‐Arnau, Nicoletta Luxi, Olaf Klungel, Patrick Souverein, Sima Mohammadi, Fabio Riefolo, Irene Pazos, Rosa Gini, Davide Messina, Giuseppe Roberto, Carlo Giaquinto, Elisa Barbieri, Luca Stona, Felipe Villalobos, Martín Solorzano, Carlo Alberto Bissacco, Antonio Gimeno, Beatriz Poblador, Mercedes Aza, Aida Moreno, Alejandro Santos, Vera Ehrenstein, Lise Skovgaard Svingel, Benjamin Randeris Johannesen, Cécile Droz‐Perroteau, Laure Carcaillon‐Bentata, Anna‐Mija Tolppanen, Sirpa Hartikainen, Thuan Vo, Anne Paakinaho, Blair Rajamaki, Hedvig Nordeng, Saeed Hayati, Mahmoud Zidan, Juan José Carreras Martínez, Arantxa Urchueguía Fornes, Elisa Correcher Martínez, Javier Díez‐Domingo, Mar Martin, Patricia Garcia‐Poza, Airam de Burgos, Belén Castillo‐Cano, Elisa Martín‐Merino   +62 more
wiley   +1 more source

Accelerated BEP : a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour [PDF]

, 2011
Background: We used bleomycin, etoposide, cisplatin (BEP), the most effective regimen in the treatment of germ cell tumours (GCTs) and increased dose-density by using pegfilgrastim to shorten cycle length. Our aim was to assess safety and tolerability.
Armstrong, G. (Georgina), Chester, John, Joffe, Johnathan, Mazhar, Danish, Parashar, D., Powles, Thomas, Rimmer, Yvonne, Shamash, Jonathan, Stark, Daniel, Wason, James, White, J., Williams, M. V.   +11 more
core   +1 more source

Impact of Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors on Anti‐PD‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

Cancer Science, Volume 117, Issue 4, Page 929-942, April 2026.
Ramucirumab (RAM) plus docetaxel (DOC) after PD‐1 inhibitors showed clinical activity, with responders exhibiting maintained anti–PD‐1 (IgG4+)‐bound CD8+ T cells and decreased IgG4+ Tregs. A sequential strategy of administering RAM plus DOC during persistent anti–PD‐1 antibody binding may be beneficial in patients with advanced non‐small cell lung ...
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya, Kyoichi Okishio, Yuhei Kinehara, Tomoki Kuge, Masahide Mori, Shingo Satoh, Hidekazu Suzuki, Satoshi Tetsumoto, Toshie Niki, Yasuhiko Suga, Akio Osa, Toshiyuki Minami, Shohei Koyama, Yoshito Takeda, Nobuyuki Takakura, Atsushi Kumanogoh   +20 more
wiley   +1 more source

Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis

Journal of Neuroinflammation, 2011
Background Granulocyte colony stimulating factor (GCSF) is protective in animal models of various neurodegenerative diseases. We investigated whether pegfilgrastim, GCSF with sustained action, is protective in a mouse model of amyotrophic lateral ...
Giniatullina Raisa, Goldsteins Gundars, Ahtoniemi Toni, Wojciechowski Sara, Malm Tarja, Kanninen Katja, Jaronen Merja, Savchenko Ekaterina, Pollari Eveliina, Giniatullin Rashid, Koistinaho Jari, Magga Johanna   +11 more
doaj   +1 more source

Pegfilgrastim-Induced Aortitis in a Patient with Small-Cell Lung Cancer Who Received Immunotherapy Combined with Chemotherapy

Case Reports in Oncology, 2023
Introduction: Granulocyte colony-stimulating factor (G-CSF), including pegfilgrastim, increases the peripheral blood leukocyte count and is widely used in clinical practice in combination with cytotoxic chemotherapy.
Takanori Ito, Osamu Kanai, Zentaro Saito, Takuma Imakita, Issei Oi, Kohei Fujita, Hiromasa Tachibana, Tadashi Mio   +7 more
doaj   +1 more source

Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience [PDF]

, 2016
In this prospective study, the impact of granulocyte colony-stimulating factors (G-2 CSF) administered during induction treatment with bendamustine plus rituximab for indolent non- Hodgkin Llymphoma (NHL) was evaluated by comparing patients who received ...
Catalano, Lucio, CERCHIONE, CLAUDIO, DE RENZO, AMALIA, DI PERNA, MARIA, PANE, FABRIZIO, Pepa, Roberta Della, PICARDI, MARCO, PUGLIESE, NOVELLA   +7 more
core   +2 more sources